# OnCo record paper-stampede-abiraterone-high-risk-attard-lancet-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-stampede-abiraterone-high-risk-attard-lancet-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-stampede-abiraterone-high-risk-attard-lancet-2022" ;
  schema:name "STAMPEDE: abiraterone with or without enzalutamide added to androgen deprivation for high-risk non-metastatic prostate cancer"@en ;
  schema:description "Adding two years of abiraterone to hormone therapy and radiotherapy for high-risk localised or node-positive prostate cancer halved the risk of metastases and cut deaths by 40 percent, while adding enzalutamide on top brought only extra toxicity."@en ;
  schema:url <https://onco.cc/key-papers/paper-stampede-abiraterone-high-risk-attard-lancet-2022/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(21)02437-5>, <https://pubmed.ncbi.nlm.nih.gov/34953525/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(21)02437-5> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Attard G, Murphy L, Clarke NW, et al." ;
  onco:cancers <https://onco.cc/cancers/prostate-high-risk/> ;
  onco:drugs <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/enzalutamide/> ;
  onco:trials <https://onco.cc/trials/stampede/> ;
  onco:journals <https://onco.cc/journals/lancet/> .